We live in the age of optimisation. Constantly asking questions like how can we be more efficient? How can we streamline processes? How can we enhance ourselves with the resources available? The pharmaceutical scene is no different, seeking to optimise drugs in any way possible to produce better patient outcomes. Biopharmaceutical company Starpharma (ASX: SPL)
Read More
One of the world’s most respected surgeons in the field of burns and trauma recovery will lead world-first clinical trials aiming to stop scars forming, particularly after burn injuries, utilising the latest discovery by biopharmaceuticals company Pharmaxis (ASX: PXS). The discovery, known as PXS-6302 has shown promising pre‐clinical results in inhibiting the enzymes that play
Read More
With China having lost more than 100 million pigs due to the recent outbreak of African swine fever in the mainland, attention has been thrust upon preventative measures, leading a Chinese Group to engage chemical company Zoono (ASX: ZNO) for a 10-year distribution arrangement. The Chinese Group will use the Zoono China brand to sell
Read More
Australian biopharmaceuticals developer Neuren Pharmaceuticals (ASX: NEU) has been granted a patent from the European Patent Office covering NNZ-2591, a world-first drug being developed to treat three neurodevelopmental disorders which affect children, and are currently incurable. The granting of the new patent is the third jurisdiction to do so for Neuren with the same application
Read More
Biopharmaceuticals manufacturer MGC Pharmaceuticals (ASX: MXC) has seen significant uptake of its cannabinoid medications with prescriptions across Australia and the United Kingdom doubling to 800 patients through the month of October. The update comes as more medical practitioners prescribe phytocannabinoid-derived medications CannEpil®, which targets drug-resistant epilepsy, and MXP100 which is recommended for neurological disorders, inflammation
Read More